Molindone

CHEMBL460 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

276.4 g/mol

LogP

1.7

Phase

4

An antipsychotic medication used to treat schizophrenia, working by blocking dopamine receptors in the brain.

आणविक भार

276.3700 g/mol

LogP

1.70

TPSA

45.30 Å²

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अनिद्रा उच्च रक्तचाप क्रॉनिक किडनी डिज़ीज़ जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर दर्द प्रबंधन दीर्घकालिक दर्द बाइपोलर डिसऑर्डर माइग्रेन मिर्गी (एपिलेप्सी) सिज़ोफ्रेनिया स्ट्रोक हृदय विफलता

क्रिया का तंत्र

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2

InChI

InChI=1S/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3

Molecular Formula

C16H24N2O2

HBD / HBA

1 / 3

घूर्णनीय बंधन

3

भारी परमाणु

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An antipsychotic medication used to treat schizophrenia, working by blocking dopamine receptors in the brain.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Molindone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL460. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23897. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Molindone PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C16H24N2O2

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.